Daihan Pharmaceutical Co.Ltd (023910) — Cash Flow Reinvestment Rate
Daihan Pharmaceutical Co.Ltd (023910) has a Cash Flow Reinvestment Rate of 1.44x as of September 2025, reinvesting ₩13.63 Billion (capex ₩10.79 Billion plus investments ₩-2.84 Billion) from operating cash flow of ₩9.47 Billion. Check earnings quality score of Daihan Pharmaceutical Co.Ltd to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Daihan Pharmaceutical Co.Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for Daihan Pharmaceutical Co.Ltd across 11 annual periods. Explore long-term investment intensity of Daihan Pharmaceutical Co.Ltd to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Daihan Pharmaceutical Co.Ltd (2014–2024)
Year-by-year capital reinvestment analysis for Daihan Pharmaceutical Co.Ltd. For live market cap and broader valuation context, see Daihan Pharmaceutical Co.Ltd stock valuation.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 2.48x | ₩88.43 Billion | ₩35.64 Billion | ₩15.80 Billion | ▲ +145.5% |
| 2023 | 1.01x | ₩39.28 Billion | ₩38.86 Billion | ₩21.28 Billion | ▲ +232.5% |
| 2022 | 0.30x | ₩8.81 Billion | ₩29.00 Billion | ₩8.62 Billion | ▲ +1.7% |
| 2021 | 0.30x | ₩12.13 Billion | ₩40.62 Billion | ₩11.85 Billion | ▼ -8.3% |
| 2020 | 0.33x | ₩10.96 Billion | ₩33.63 Billion | ₩5.36 Billion | ▼ -53.7% |
| 2019 | 0.70x | ₩24.84 Billion | ₩35.26 Billion | ₩17.30 Billion | ▼ -33.8% |
| 2018 | 1.06x | ₩47.80 Billion | ₩44.94 Billion | ₩46.69 Billion | ▲ +2.3% |
| 2017 | 1.04x | ₩21.26 Billion | ₩20.45 Billion | ₩21.05 Billion | ▲ +18.5% |
| 2016 | 0.88x | ₩24.50 Billion | ₩27.92 Billion | ₩21.90 Billion | ▲ +290.5% |
| 2015 | 0.22x | ₩4.04 Billion | ₩17.98 Billion | ₩3.96 Billion | ▼ -82.1% |
| 2014 | 1.26x | ₩11.90 Billion | ₩9.48 Billion | ₩10.47 Billion | — |